Silphium Asset Management’s CureVac CVAC Stock Holding History

Silphium Asset Management’s Portfolio CVAC Stock Details CVAC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-100,000	Closed	-$340K	–	55
2024 Q2	$340K	Hold	100,000	–	–	0.16%	52
2024 Q1	$303K	Sell	100,000 -75,000	-43%	-$263K	0.15%	45
2023 Q4	$737K	Buy	175,000 +25,000	+17%	+$136K	0.39%	39
2023 Q3	$1.02M	Buy	150,000 +25,000	+20%	+$221K	0.33%	52
2023 Q2	$1.3M	Buy	+125,000	New	+$1.12M	0.57%	46

Other funds holding CVAC

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Gates Foundation Seattle, Washington $43.5M AUM 14.19% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

DZ Bank Frankfurt Am Main, Germany $113B AUM 36.92% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Silphium Asset Management's CVAC Position: Q3 2024 in Review

Silphium Asset Management sold out of CureVac (CVAC) in Q3 2024, closing a stake of 100,000 shares — an estimated $340K sold.

Silphium Asset Management first reported a position in CVAC in Q2 2023 and held it in 5 quarters. The position peaked at $1.3M in Q2 2023. 81 funds tracked by Wall St. Rank hold CVAC as of Q3 2024.

Silphium Asset Management reported no remaining CureVac position as of Q3 2024 after selling out during the quarter.
Silphium Asset Management sold 100,000 CureVac shares in Q3 2024, an estimated $340K.
Silphium Asset Management first reported a position in CureVac in Q2 2023 and held it in 5 quarters.
Silphium Asset Management's CureVac position peaked at $1.3M in Q2 2023.
81 funds tracked by Wall St. Rank held CureVac as of Q3 2024.

Based on Silphium Asset Management's 13F filing for Q3 2024, filed 30 Jan 2025.